Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385515
Status:
COMPLETED
Last Update Posted:
2009-05-07
First Post:
2006-10-05
Brief Title:
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Sponsor:
Mucosal Therapeutics
Organization:
Mucosal Therapeutics
Study Overview
Official Title:
A Phase 2 Randomized Double-Masked Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Oral mucositis OM is a common and debilitating toxicity induced by many chemotherapy CT regimens and by radiation to the head and neck The purpose of this study is to determine the effectiveness of SNX-1012 in decreasing the duration of Grade 2 3 or 4 oral mucositis OM according to World Health Organization WHO criteria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None